Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report
| Autor: | Kosuke Miyai, Keiichi Ito, Yuichi Arai, Akio Horiguchi, Mina Hatanaka, Hirofumi Hashimoto, Yosuke Kitamura |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment axitinib periodic drug withdrawal schedule 03 medical and health sciences 0302 clinical medicine type 2 papillary renal cell carcinoma medicine Lymph node Papillary renal cell carcinomas business.industry Sunitinib Articles Nephrectomy Temsirolimus Axitinib Zoledronic acid medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Radiology Metastasectomy business metastasectomy medicine.drug |
| Zdroj: | Molecular and Clinical Oncology |
| ISSN: | 2049-9450 |
| Popis: | A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lung metastasis was performed one month after the nephrectomy. Mediastinal LN metastases occurred in 2013, and resection of the affected LNs was performed. Sunitinib and zoledronic acid was started in 2014 because mediastinal LN swelling and multiple bone metastases appeared. Sunitinib treatment was stopped soon after due to adverse events and axitinib treatment was started. Axitinib was effective and the patient had stable disease for 30 months. Adverse events were successfully controlled by dose reduction and periodic drug withdrawal schedules (for example, 5 days on, 2 days off). Axitinib was further continued for 19 months as the metastatic lesions had progressed slowly. Temsirolimus treatment was started in 2019, but it was stopped after three cycles due to interstitial pneumonia. The patient died 80 months after the initial recurrence. Using multidisciplinary treatment, durable disease control was achieved in a patient with metastatic type 2 PRCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|